D R Horton Inc vs Twist Bioscience Corp — how do they compare? D R Horton Inc trades at $133.59 (market cap $37.99B), while Twist Bioscience Corp trades at $160 (market cap $10.08B). The key difference: D R Horton Inc is far larger — about 3.8× Twist Bioscience Corp's market cap, and D R Horton Inc pays a 1.33% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Twist Bioscience Corp for 27 Days on average.
| DHI | TWST | |
|---|---|---|
Market Cap | $37.99B | $10.08B |
Volume | 2,974,460 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $205.00 |
52-Week Low | $132.53 | $25.45 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | $43.09B | $10.01B |
Dividend Yield | 1.33% | — |
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →